Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)

Annals of Oncology

Volumn 28, Issue 3, 2017, Pages 651-657

  Mesnage, S J L ^a   Auguste, A ^a,b   Genestie, C ^a   Dunant, A ^a   Pain, E ^a   Drusch, F ^a   Gouy, S ^a   Morice, P ^a   Bentivegna, E ^a   Lhomme, C ^a   Pautier, P ^a   Michels, J ^a   Le Formal, A ^a,b   Cheaib, B ^a   Adam, J ^a   Leary, Alexandra F ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Epithelial ovarian cancer; Neoadjuvant chemotherapy; PD L1; Tumour infiltrating lymphocytes

Indexed keywords

CISPLATIN; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CYTOREDUCTIVE SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; CD8+ T LYMPHOCYTE; DISEASE FREE SURVIVAL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; B7-H1 ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 85018363790     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw625     Document Type: Article

References (22)

1. Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-18543.
2. Clarke B, Tinker AV, Lee CH et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009; 22: 393-402.
3. Hamanishi J, Mandai M, IwasakiMet al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007; 104: 3360-3365.
4. Hwang WT, Adams SF, Tahirovic E et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012; 124: 192-198.
5. Wouters MC, Komdeur FL, Workel HH et al. Treatment regimen, surgical outcome, and T-cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high-grade serous ovarian cancer. Clin Cancer Res 2016; 22: 714-724.
6. Peng J, Hamanishi J, Matsumura N et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 2015; 75: 5034-5045.
7. Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959-2966.
8. Salgado R, Denkert C, Demaria S et al. The evaluation of tumorinfiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259-271.
9. Vergote I, Trope CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-953.
10. Coukos G, Tanyi J, Kandalaft LE. Opportunities in immunotherapy of ovarian cancer. Ann Oncol 2016; 27 (Suppl 1): i11-i15.
11. Hamanishi J, Mandai M, Ikeda T et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015; 33: 4015-4022.
12. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
13. McShane LM, Altman DG, SauerbreiWet al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23: 9067-9072.
14. Schimizu Y, Kamoi S, Amada S et al. Toward the development of a universal grading system for ovarian epithelial carcinoma:Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1988; 82: 893-901.
15. Bohm S, Montfort A, Pearce OM et al. Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clin Cancer Res 2016; 22: 3025-3036.
16. Webb JR, Milne K, Kroeger DR, Nelson BH. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in highgrade serous ovarian cancer. Gynecol Oncol 2016; 141: 293-302.
17. Romano E, Romero P. The therapeutic promise of disrupting the PD-1/ PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. J Immunother Cancer 2015; 3: 15.
18. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571.
19. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567.
20. Polcher M, Braun M, Friedrichs N et al. Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. Cancer Immunol Immunother 2010; 59: 909-919.
21. Denkert C, von Minckwitz G, Brase JC et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triplenegative primary breast cancers. J Clin Oncol 2015; 33: 983-991.
22. Dieci MV, Criscitiello C, Goubar A et al. Prognostic value of tumorinfiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol 2014; 25: 611-618.